Project Grant R01CA286444
Award Date
3/1/24
Completion Date
2/28/29
Dollars Obligated
$613K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $718,113 to St. Jude Children's Research Hospital to investigate the role of epigenetic modifiers in promoting neuroblastoma cancer progression and treatment resistance. Specifically, the research aims to understand how transcription factors MYC and TCF4 interact with epigenetic regulators like histone deacetylases (HDACs) and lysine demethylases...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research Program (CFDA 93.395) provides $738,024 to St. Jude Children's Research Hospital to develop chemical probes to study the chromatin binding domains of the BPTF protein in neuroblastoma, an aggressive pediatric cancer. The goal is to understand how BPTF, a key component of the NURF chromatin remodeling complex, regulates oncogenic pathways involving MYC and MYCN in neuroblastoma and to use this...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The $562,869 award to Children's Hospital Los Angeles, a leading pediatric academic medical center, will fund a 5-year research project to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,197,216.00 to St. Jude Children's Research Hospital Inc. to advance the understanding of biologically and clinically distinct subtypes of pineoblastoma, a rare and aggressive pediatric brain cancer. The research program aims to delineate the cellular origins and developmental pathways underlying the four newly defined pineoblastoma subgroups to resolve oncogenic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $600,079 to The Washington University in St. Louis to develop and evaluate a novel combination therapy for relapsed and refractory neuroblastoma, the most common extracranial solid cancer in children. The researchers will deploy two next-generation targeted radiotherapies - 77Br-MBBG (an auger-emitting norepinephrine transporter ligand) and 227Th-L804-LM3 (a thorium-227 alpha-emitting...
This National Cancer Institute (CFDA 93.396 - Cancer Biology Research) Project Grant award of $447,944 to Baylor College of Medicine supports research to characterize the role of the transcription factor NRF2 in driving metastasis and therapy resistance in high-risk pediatric hepatoblastoma (HB) patients. The overarching goal is to thoroughly elucidate the molecular mechanisms underlying HB tumor cell dissemination, which can inform the development of targeted therapies to minimize metastasis,...
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), has awarded a $601,250 Cooperative Agreement to St. Jude Children's Research Hospital Inc. The project, titled "Discovering the Mechanisms Underlying Oncogenesis by ZFTA-RELA and Pinpointing Therapeutic Targets," aims to investigate the biology and therapeutic vulnerabilities of the ZFTA-RELA fusion oncogene, a key driver of the aggressive pediatric brain tumor ependymoma. The...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 Biomedical Research and Research Training, provides $125,000 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research aimed at understanding the molecular mechanisms underlying transcriptional regulation in the context of pediatric cancers. The key research objectives are to: 1) Determine the high-resolution 3D structure of the ZMYM2-KDM1A-CoREST complex to gain...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) Federal Grant Program provides $148,568 to St. Jude Children's Research Hospital Inc. to conduct research on the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The research aims to gain mechanistic insights into the interplay between the SWI/SNF chromatin remodeling complex and the polycomb complex, which is disrupted in cancer. The project will use...
This $635,173 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the mechanisms by which the MYCN oncogene promotes an immunosuppressive tumor microenvironment in high-risk neuroblastoma. The research team, led by investigators at Boston University Medical Campus, will leverage zebrafish models and human patient samples...